TM
ENTA icon

Torren Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Torren Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$860 Hold
59
– – ﹤0.01% 766
2026
Q1 		$745 Sell
59
-61
-51% -$818 ﹤0.01% 801
2025
Q4 		$1.89K Buy
+120
New +$1.52K ﹤0.01% 1075

Other funds holding ENTA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Torren Management's ENTA Position: Q2 2026 in Review

Torren Management held its Enanta Pharmaceuticals (ENTA) position steady in Q2 2026 at 59 shares worth $860. The position accounts for ﹤0.01% of the portfolio, ranked #766.

Torren Management first reported a position in ENTA in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.89K in Q4 2025. 40 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Torren Management held 59 shares of Enanta Pharmaceuticals worth $860 as of Q2 2026.
  • Torren Management left its Enanta Pharmaceuticals share count unchanged in Q2 2026.
  • Enanta Pharmaceuticals made up ﹤0.01% of Torren Management's portfolio in Q2 2026, its #766 holding.
  • Torren Management first reported a position in Enanta Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Torren Management's Enanta Pharmaceuticals position peaked at $1.89K in Q4 2025.
  • 40 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Torren Management's 13F filing for Q2 2026, filed 10 Jul 2026.